However, PLEKHA4 was down-regulated in adrenocortical carcinoma (ACC), BLCA, BRCA, colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), KICH, acute myeloid leukemia (LAML), LIHC, LUAD, LUSC, ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD) and UCEC, compared to GTEx normal controls. Here, PLEKHA4 is linked to bladder transitional cell carcinoma.